Syros Pharmaceuticals
Stock Forecast, Prediction & Price Target
Syros Pharmaceuticals (SYRS) stock Price Target by analysts
$5
Potential upside: 90809.09%
Syros Pharmaceuticals price prediction
What is Syros Pharmaceuticals stock analysts` prediction?
Syros Pharmaceuticals stock forecast: Based on 1 Wall Street analysts` predicted price targets for Syros Pharmaceuticals in the last 3 months, the avarage price target is $5, with a high forecast of $NaN. The average price target represents a 90809.09% change from the last price of $0.01.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Syros Pharmaceuticals stock Price Target by analysts
Full breakdown of analysts given Syros Pharmaceuticals price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Edward Tenthoff Piper Sandler | 0% 0/3 | 11 months ago | $5 90809.09% upside | $2.47 | StreetInsider | Previous targets (2) |
Edward Tenthoff Piper Sandler | 0% 0/3 | about 1 year ago | $13 236263.63% upside | $5.7 | StreetInsider | Previous targets (2) |
Andrew Fein H.C. Wainwright | 0% 0/1 | about 1 year ago | $15 272627.27% upside | $5.7 | StreetInsider | Previous targets (0) |
Edward Tenthoff Piper Sandler | 0% 0/3 | almost 3 years ago | $27 490809.09% upside | $6.08 | TheFly | Previous targets (2) |
Mark Breidenbach Oppenheimer | 100% 1/1 | about 3 years ago | $3 54445.45% upside | $9.27 | TheFly | Previous targets (0) |
Unknown H.C. Wainwright | N/A | about 3 years ago | $6 108990.90% upside | $0.86 | Benzinga | N/A |
Unknown H.C. Wainwright | N/A | over 3 years ago | $10 181718.18% upside | $0.77 | Benzinga | N/A |
Syros Pharmaceuticals Financial Estimates
Syros Pharmaceuticals Revenue Estimates
Syros Pharmaceuticals EBITDA Estimates
Syros Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $23.48M N/A | $14.88M -36.64% | $9.93M -33.22% | Avg: $32.08M Low: $2.36M High: $61.79M avg. 222.86% | Avg: $151.16M Low: $20.79M High: $281.54M avg. 371.21% | Avg: $335.56M Low: $46.15M High: $624.97M avg. 121.98% | Avg: $536.53M Low: $73.80M High: $999.26M avg. 59.88% |
Net Income
% change YoY
| $-90.46M N/A | $-49.30M 45.50% | $-164.57M -233.81% | Avg: $-106.49M Low: $-116.41M High: $-21.81M avg. 35.29% | Avg: $-37.03M Low: $-66.84M High: $45.88M avg. 65.22% | Avg: $45.60M Low: $-5.52M High: $96.73M avg. 223.14% | Avg: $144.90M Low: $-17.56M High: $307.37M avg. 217.75% |
EBITDA
% change YoY
| $-96.31M N/A | $-130.77M -35.77% | $-157.19M -20.20% | Avg: $-32.08M Low: $-61.79M High: $-2.36M avg. 79.59% | Avg: $-151.16M Low: $-281.54M High: $-20.79M avg. -371.21% | Avg: $-335.56M Low: $-624.97M High: $-46.15M avg. -121.98% | Avg: $-536.53M Low: $-999.26M High: $-73.80M avg. -59.88% |
EPS
% change YoY
| -$14.47 N/A | -$3.9 73.04% | -$5.81 -48.97% | Avg: -$2.6 Low: -$4.11 High: -$0.77 avg. 55.31% | Avg: -$0.8 Low: -$2.36 High: $1.62 avg. 69.31% | Avg: $1.61 Low: -$0.2 High: $3.42 avg. 302.09% | Avg: $5.12 Low: -$0.62 High: $10.85 avg. 217.75% |
Operating Expenses
% change YoY
| $122.90M N/A | $141.24M 14.91% | $138.92M -1.64% | Avg: $115.78M Low: $8.55M High: $223.01M avg. -16.65% | Avg: $545.57M Low: $75.04M High: $1.01B avg. 371.21% | Avg: $1.21B Low: $166.58M High: $2.25B avg. 121.98% | Avg: $1.93B Low: $266.35M High: $3.60B avg. 59.88% |
FAQ
What is Syros Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 135.35% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -116.41M, average is -106.49M and high is -21.81M.
What is Syros Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 193.98% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $2.36M, average is $32.08M and high is $61.79M.
What is Syros Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 161.11% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$4.11, average is -$2.6 and high is $-0.77.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Syros Pharmaceuticals stock. The most successful analyst is Edward Tenthoff.